

blood

2007 110: 1388-1396
Prepublished online Apr 23, 2007;
doi:10.1182/blood-2007-02-072389

High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study

Richard A. Nash, Peter A. McSweeney, Leslie J. Crofford, Muneer Abidi, Chien-Shing Chen, J. David Godwin, Theodore A. Gooley, Leona Holmberg, Gretchen Henstorf, C. Fred LeMaistre, Maureen D. Mayes, Kevin T. McDonagh, Bernadette McLaughlin, Jerry A. Molitor, J. Lee Nelson, Howard Shulman, Rainer Storb, Federico Viganego, Mark H. Wener, James R. Seibold, Keith M. Sullivan and Daniel E. Furst

Updated information and services can be found at:

<http://bloodjournal.hematologylibrary.org/cgi/content/full/110/4/1388>

Articles on similar topics may be found in the following *Blood* collections:

[Transplantation](#) (1230 articles)

[Immunotherapy](#) (567 articles)

[Clinical Trials and Observations](#) (2240 articles)

Information about reproducing this article in parts or in its entirety may be found online at:

http://bloodjournal.hematologylibrary.org/misc/rights.dtl#repub_requests

Information about ordering reprints may be found online at:

<http://bloodjournal.hematologylibrary.org/misc/rights.dtl#reprints>

Information about subscriptions and ASH membership may be found online at:

<http://bloodjournal.hematologylibrary.org/subscriptions/index.dtl>

Blood (print ISSN 0006-4971, online ISSN 1528-0020), is published semimonthly by the American Society of Hematology, 1900 M St, NW, Suite 200, Washington DC 20036.

Copyright 2007 by The American Society of Hematology; all rights reserved.



High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study

Richard A. Nash,^{1,2} Peter A. McSweeney,³ Leslie J. Crofford,⁴ Muneer Abidi,⁵ Chien-Shing Chen,⁶ J. David Godwin,² Theodore A. Gooley,^{1,2} Leona Holmberg,^{1,2} Gretchen Henstorf,¹ C. Fred LeMaistre,⁷ Maureen D. Mayes,⁸ Kevin T. McDonagh,⁴ Bernadette McLaughlin,¹ Jerry A. Molitor,⁹ J. Lee Nelson,^{1,2} Howard Shulman,^{1,2} Rainer Storb,^{1,2} Federico Viganego,¹ Mark H. Wener,² James R. Seibold,¹⁰ Keith M. Sullivan,¹¹ and Daniel E. Furst¹²

¹Fred Hutchinson Cancer Research Center, Seattle, WA; ²University of Washington, Seattle; ³Rocky Mountain Cancer Center, Denver, CO; ⁴University of Kentucky, Lexington; ⁵Wayne State University, Detroit, MI; ⁶Loma Linda University, CA; ⁷Texas Transplant Institute, San Antonio; ⁸University of Texas Health Science Center, Houston; ⁹Virginia-Mason Medical Center, Seattle, WA; ¹⁰University of Michigan, Ann Arbor; ¹¹Duke University Medical Center, Durham, NC; and ¹²University of California, Los Angeles

More effective therapeutic strategies are required for patients with poor-prognosis systemic sclerosis (SSc). A phase 2 single-arm study of high-dose immunosuppressive therapy (HDIT) and autologous CD34-selected hematopoietic cell transplantation (HCT) was conducted in 34 patients with diffuse cutaneous SSc. HDIT included total body irradiation (800 cGy) with lung shielding, cyclophosphamide (120 mg/kg), and equine antithymocyte globulin (90 mg/kg). Neutrophil and platelet counts were recovered by 9 (range, 7 to 13) and 11 (range, 7 to

25) days after HCT, respectively. Seventeen of 27 (63%) evaluable patients who survived at least 1 year after HDIT had sustained responses at a median follow-up of 4 (range, 1 to 8) years. There was a major improvement in skin (modified Rodnan skin score, -22.08 ; $P < .001$) and overall function (modified Health Assessment Questionnaire Disability Index, -1.03 ; $P < .001$) at final evaluation. Importantly, for the first time, biopsies confirmed a statistically significant decrease of dermal fibrosis compared with baseline ($P < .001$). Lung, heart, and kidney func-

tion, in general, remained clinically stable. There were 12 deaths during the study (transplantation-related, 8; SSc-related, 4). The estimated progression-free survival was 64% at 5 years. Sustained responses including a decrease in dermal fibrosis were observed exceeding those previously reported with other therapies. HDIT and autologous HCT for SSc should be evaluated in a randomized clinical trial. (Blood. 2007;110:1388-1396)

© 2007 by The American Society of Hematology

Introduction

Systemic sclerosis (SSc) is a multisystem autoimmune disease with vasculopathy and progressive fibrosis that is highly variable in its clinical manifestations, but patients with diffuse cutaneous SSc and internal organ involvement have reduced life span.¹⁻⁴ Although cyclophosphamide was recently observed to have a small beneficial effect, more effective therapies for the severe forms of SSc are required to improve outcome.⁵⁻⁹ In a report of the first 19 patients in this pilot study, it was observed that there was marked clinical improvement in the degree of the scleroderma and overall function with a median follow-up of 15 months.¹⁰ Now, in 34 patients, we report additional information on safety and show that there was a significant decrease in the degree of the scleroderma and dermal fibrosis, improved overall function and, in general, stability of internal organ function, and these responses were sustained at a median of 4 years after high-dose immunosuppressive therapy (HDIT).

Patients, materials, and methods

Patients

Between July 1997 and March 2005, 34 participants were enrolled in the study at the Fred Hutchinson Cancer Research Center (n = 19), University

of Michigan (n = 7), Karmanos Cancer Institute (n = 4), Loma Linda University (n = 3), and Texas Transplant Institute (n = 1). The institutional review board at each center approved the study. Patients were registered for the study only after providing a signed consent to confirm that they had been fully informed, in accordance with the Declaration of Helsinki, of the investigational purposes of the study.

Study design

This pilot study was designed to assess the safety and potential efficacy of HDIT for severe SSc. Patients 65 years of age or less were eligible for study participation if they had early (4 years or less) diffuse scleroderma (modified Rodnan skin score [mRSS] 16 or greater) and significant visceral organ involvement as previously described.¹⁰ Patients were also included if there was progressive pulmonary disease with a decrease of at least 15% in forced vital capacity (FVC) or diffusion capacity of the lung for carbon monoxide adjusted for hemoglobin levels (DLCO_{adj}) in the previous 6 months with any skin involvement. The eligibility criteria selected patients with a mortality risk from SSc of approximately 50% at 5 years with conventional treatment, and these have been previously published.⁹⁻¹¹ Study end points were safety of mobilization with granulocyte colony-stimulating factor (G-CSF), engraftment after transplantation of autologous CD34-selected hematopoietic cells (HCs), early and late regimen-related

Submitted February 6, 2007; accepted April 16, 2007. Prepublished online as *Blood* First Edition paper, April 23, 2007; DOI 10.1182/blood-2007-02-072389.

An Inside *Blood* analysis of this article appears at the front of this issue.

The publication costs of this article were defrayed in part by page charge

payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.

© 2007 by The American Society of Hematology

toxicity or complications, disease response, and immunologic recovery. Immune recovery of the study participants has been reported previously.^{10,12}

Treatment and supportive care

Peripheral blood stem cells (PBSCs) were mobilized with G-CSF (16 $\mu\text{g}/\text{kg}/\text{d}$) subcutaneously with the first apheresis scheduled on day 4. The G-CSF–mobilized PBSC products were CD34–selected using a Isolex 300i device (Baxter, Irvine, CA) and cryopreserved. Unmodified autologous HC grafts were stored for treating engraftment failure or severe immunodeficiency after HDIT. The autologous HC grafts were evaluated for content of CD34⁺ cells and CD3⁺ T cells by flow cytometry. The HDIT regimen has been previously reported and included fractionated total body irradiation (TBI) 800 cGy, cyclophosphamide (120 mg/kg), and equine antithymocyte globulin ([ATG] 90 mg/kg; Pfizer, New York, NY).¹⁰ Methylprednisolone (1 mg/kg) was given intravenously with each dose of ATG. TBI without lung shielding was used for the first 8 patients, and subsequently lungs were shielded to a total dose of 200 cGy. Prednisone (0.5 mg/kg/d) was given from the start of conditioning to day 30 after hematopoietic cell transplantation (HCT) and was tapered over 1 month after the fifth patient included in the study. The CD34–selected autologous graft was infused on day 0. G-CSF (5 $\mu\text{g}/\text{kg}/\text{d}$) was given intravenously from day 0 until the absolute neutrophil count was greater than $0.5 \times 10^9/\text{L}$ ($500/\mu\text{L}$) for 3 days. Infection prophylaxis included trimethoprim-sulfamethoxazole, acyclovir, and fluconazole.¹³ A preemptive strategy was used for the prevention of cytomegalovirus (CMV) disease.¹⁴

Evaluation of outcomes

The day of neutrophil engraftment was defined as the first of 3 consecutive days after HCT when an absolute count of greater than $0.5 \times 10^9/\text{L}$ ($500/\mu\text{L}$) had been achieved. The day of platelet engraftment was defined as the first of 3 consecutive days when a count of $20 \times 10^9/\text{L}$ ($20\,000/\mu\text{L}$) had been sustained or the first of 2 days in which the platelet count increased on the second day without transfusions.¹⁵ Regimen-related toxicities were defined according to the Bearman scale.¹⁶

Scheduled evaluations of patients were performed before mobilization and then at 3 months and annually after HCT. These evaluations included a medical history, physical examination, complete blood count, serum chemistries, autoantibodies (Scl-70, ANA), thyroid function tests, validated standard measurements of the mRSS, pulmonary function testing for FVC and DLCO_{adj}, high-resolution computed tomography (HRCT) scans of the chest, multigated acquisition (MUGA) scan of the heart or echocardiogram for left ventricular ejection fraction (LVEF), and a modified Health Assessment Questionnaire Disability Index (mHAQ-DI).^{5,17-21} An ophthalmologic examination was done at the last study evaluation to assess for cataracts. In a subset of consenting patients, skin biopsies were done after HDIT next to the site of the baseline biopsy.

For determining progression-free survival, progression was defined as death, respiratory failure (decrease in FVC of more than 20% or decrease in DLCO_{adj} of more than 30%), renal failure (requiring chronic dialysis for more than 6 months), or heart failure (LVEF less than 30%) after HDIT. Progression could be treatment related or disease related. Disease activation was defined as events developing 6 or more months after HDIT, including worsening pulmonary function (decrease in FVC of more than 10% or DLCO_{adj} of more than 15%), arrhythmias requiring medical treatment for 3 or more months, onset of hypertensive or nonhypertensive renal crisis, increase in mRSS (5 or more for baseline of up to 20, or more than 25% for baseline more than 20), increase in mHAQ (more than 0.4), or the initiation

of disease-modifying antirheumatic drugs (DMARDs). Disease response was defined as a decrease in mRSS (5 or more for baseline of up to 20, or more than 25% for baseline more than 20), improving pulmonary function (increase in FVC of more than 10% or DLCO_{adj} of more than 15%), or a decrease in mHAQ (more than 0.4). Only patients who survived at least 1 year were considered evaluable for response because there were no scheduled evaluations performed 3 to 12 months after HDIT, and the duration of follow-up at 3 months was not adequate for evaluating response endpoints of fibrosis and organ function.

Assessment of skin biopsies

Serial 3- to 4-mm full-thickness punch biopsies of skin were taken from the same location in an individual patient, either the lateral aspect of the forearm or the upper arm in the triceps region, in a subset of patients. Coded slides stained with hematoxylin and eosin (H&E) were prepared from formalin-fixed blocks and were analyzed for changes in the various components of skin, including epidermis, papillary and reticular dermis, adnexae, and subcutis. Deidentification and coding of the slides was done so that a blinded evaluation of the dermal fibrosis could be performed. The histologic sections of the skin were assessed on a Leica DM 3000 microscope (Leica Microsystems, Wetzlar, Germany), relying primarily on the 2.5 \times nplan/0.07 NA, 5 \times nplan/0.12 NA, and 10 \times /hc plan Fluotar/0.30 NA objectives, and also using a 20 \times HC plan apo/0.70 NA. Images were processed using Adobe Elements 4.0 and Adobe Photoshop CS version 8. Changes in fibrosis were graded on a 0-to-5 semiquantitative scale (Table 1; Figure 1). Because of the local variability in skin, even within a given location, and some qualitative variability between biopsies, a meaningful reduction in overall fibrosis score required changes of at least 2 grades.

Statistics

For each of the clinical parameters assessed, posttransplantation values were compared with pretransplantation (baseline) values at the last time point in each of several posttransplantation time windows. The 1-sample *t* test was used to test the null hypothesis that the difference between posttransplantation and baseline values was equal to 0. In addition to comparisons in specific time windows, generalized estimating equations (GEEs) were used to determine if the value of a clinical parameter increased or decreased with time (from baseline to the last measurement available). For these analyses, we tested for linear associations between time and each clinical parameter. All reported *P* values are 2-sided, and those resulting from regression models were derived from the Wald test.

Results

Patient characteristics

Patient characteristics at baseline are described in Table 2. All patients were considered to have a poor prognosis and had failed a median of 2 (range, 0 to 5) different immune-modifying treatments before being included in the clinical trial. All patients had pulmonary disease, although this may not have been the primary internal organ considered for protocol eligibility. The only patient with a skin score less than 16 (1 subject with an mRSS of 3) had progressive pulmonary disease and a DLCO_{adj} of 48%. One patient had pulmonary arterial hypertension, 1 patient required total parenteral nutrition, 3 patients had a history of significant renal

Table 1. Grading of dermal fibrosis in systemic sclerosis

Dermal fibrosis grade	Description
0	No homogenization but there may be atrophic, thin straightened collagen bundles with increased amounts of interstitial ground substance
1	Less than 25% sclerosis with residual foci; some residual straightening or eosinophilic collagen bundles may be present
2	Focal sclerosis—less than 50% overall
3	Incomplete homogenization with spaces between the collagen bundles with 50% to 75% sclerotic change
4	Pandermal sclerosis without obvious expansion of the lower reticular dermis with some sparing of perieccrine adipose tissue
5	Pandermal sclerosis with homogenization from the papillary to the reticular dermis; includes obvious widening of the reticular dermis below the eccrine coils with extension into the hypodermis and formation of fibrous septa




Figure 1. Dermal fibrosis grades 0 to 5. Each pair represents a different dermal fibrosis grade. The left-hand column of each pair containing low-power views (original magnification, $\times 2.5$), illustrates the spectrum of change in the overall dermal breadth and distribution of fibrosis. The right-hand column views for each pair (original magnification, $\times 10$), illustrate the qualitative size, shape, distribution, and density in the dermal collagen bundles and surrounding extracellular matrix. All sections are stained with H&E. Grade 0 is thin curlicue collagen bundles with only minimal focal papillary dermal sclerosis. Grade 1 is less than 25% sclerosis with focal dense deep dermal fibrosis. In grade 2, the dense zone of fibrosis within the hypodermis comprises less than 50% of the overall dermal breadth. The remaining reticular dermis is composed of fine collagen bundles with actinic change (blue) in the upper dermis. Higher power shows the distinction between the sclerotic and normal collagen bundles. Grade 3 is extensive sclerosis—more than 50%—throughout the dermis with thickened collagen bundles admixed with thinner bundles and intervening extracellular matrix. Grade 4 is pandermal fibrosis with loss of most extracellular matrix without extension into hypodermis (or entrapment of eccrine coils) or surrounding fat. Grade 5 is markedly fibrotic and thickened—more than 4 mm—dermis replaced with dense waxy collagen with deep extension into hypodermis with fibrous incorporation of a muscular artery. See “Patients and methods; Assessment of skin biopsies” for more information on images.

Table 2. Patient characteristics before transplantation (n = 34)

Clinical parameter	Value	Frequency, no.*
Median age, y (range)	41 (23-61)	34
Sex: M/F	8/26	34
Median skin score: mRSS (range)	30 (3-48)	34
Median DLCO _{adj} , † % (range)	61 (40-83)	33
Median FVC, % (range)	71 (27-103)	34
HRCT of chest		
Abnormal	27	34
Ground-glass	12	34
Interstitial fibrosis	25	34
Normal	7	34
Alveolitis by BAL	16	25
Median ejection fraction, % (range)	65 (47-80)	32
Median serum creatinine level, mg/dL (range)	0.7 (0.4-1.7)	34
Median mHAQ score (range)	1.88 (0.25-2.88)	30
Hypothyroidism	9	34
Organ dysfunction		
Lung‡	34	34
Kidney§	2	34
Heart	9	34
Gastrointestinal tract¶	23	34
Autoantibodies		
Antinuclear antibodies	25	33
Scl-70	11	34
Anticentromere	0	27
Disease duration, mo (range)#	21 (4-51)	34
Immune-based therapy before HDIT		
Corticosteroids	22	34
Cyclophosphamide	15	34
Methotrexate	13	34
D-penicillamine	10	34
Hydroxychloroquine	6	34
Etanercept	5	34
Cyclosporine	3	34
Relaxin	2	34
Imuran	1	34
Other	4	34

BAL indicates bronchoalveolar lavage.

*Number of patients with available results for the given parameter.

†Adjusted for hemoglobin concentration.

‡Lung dysfunction was defined as diffusion capacity of the lung for carbon monoxide adjusted for hemoglobin levels below 70% and/or forced vital capacity below 70%.

§Renal dysfunction was defined as prior history of renal crisis.

||Cardiac dysfunction was defined as ejection fraction below 50%, electrical conduction abnormalities, pulmonary hypertension, or pericardial effusion.

¶Gastrointestinal dysfunction was defined as esophageal or bowel dysfunction including a history of parenteral nutrition.

#Time from onset of first non-Raynaud symptoms.

dysfunction or renal crisis, and 5 patients had gastric antral vascular ectasia before HDIT.

Autologous hematopoietic cell graft and engraftment

The number of aphereses for collection of the graft, graft composition, and time to engraftment are described in Table 3. Recovery of neutrophil counts occurred in all patients at a median of 9 (range, 7 to 13) days. All patients recovered platelet counts at a median of 11 (range, 7 to 25) days except for 1 patient who developed scleroderma renal crisis. However, engraftment had occurred in this patient based on the presence of marrow megakaryocytes on day 34.

Disease evaluations

Of the 34 patients enrolled in the study, 27 (79%) survived 1 year and were evaluable for response. Summarized in Table 4 are changes from baseline to the last evaluation within various time windows for each of the clinical parameters that were assessed. The mean decrease in mRSS (baseline, 30.12) and mHAQ score (baseline, 1.85) at final evaluation was 22.08 (−70.3%) and 1.03 (−55%), respectively (both $P < .001$). There was also a statistically significant linear decrease in mRSS and mHAQ scores over time (both $P < .001$, GEE; Figure 2A,B). At last follow-up, an mRSS of 0 to 5 was observed in 11 patients. Marked improvement of mRSS was also associated with improvement of the dermal fibrosis in 8 of 10 patients for whom biopsies were available from both before and after HDIT (mean decrease, 19.6; 95% confidence interval [CI], 12.6 to 26.6; $P < .001$; Figures 3, 4). There was a mean decrease in the dermal fibrosis grade of 3.1 (95% CI, 2.2 to

Table 3. Apheresis, graft composition, and engraftment

	Median (range)
Mobilization: no. of apheresis + back-up*	2 (2-7)
CD34-selected grafts	
CD34 ⁺ cells $\times 10^6$ /kg	4.02 (2.36-8.6)
CD3 ⁺ cells $\times 10^4$ /kg; n = 22	1.86 (0-25.2)
CD34 purity (%)	91 (55-99)
Engraftment after transplantation	
Days to neutrophil count above 500/ μ L†	9 (7-13)
Days to platelet count above 20 000/ μ L‡	11 (7-25)

*Minor complications observed infrequently during mobilization included edema, increased skin tightness, erythema, and arthralgias, but these resolved after G-CSF was stopped. All grafts were collected with a single course of G-CSF except for 1 patient who had discontinued mycophenolate mofetil immediately before starting collection of peripheral blood stem cells.

†First of 3 consecutive days with an absolute neutrophil count above 500/ μ L.

‡First of 3 consecutive days with a platelet count above 20 000/ μ L or an increase in platelet count independent of platelet transfusions.

Table 4. Change in clinical parameters after HDIT

Assessments	Mean baseline; n = 34	Difference from baseline (CI; P)*					Final evaluation;†	n
		Years 1-2	Years 3-4	Years 5-8	n	n		
mRSS (0-51)	30.12	-17.56 (-20.72, -14.40; <.001)	-21.24 (-25.42, -17.05; <.001)	-21.82 (-25.88, -17.74; <.001)	21	11	-22.08 (-25.71, -18.45; <.001)	25
mHAQ (0-3)	1.85	-1.26 (-1.60, -0.92; <.001)	-1.08 (-1.53, -0.64; <.001)	-1.50 (-1.92, -1.09; <.001)	20	11	-1.03 (-1.40, -0.66; <.001)	26
DLCO _{adj} , %	60.09	-1.37 (-5.64, 4.98; .60)	-3.70 (-9.86, 4.90; .31)	-2.27 (-9.69, 5.15; P .51)	23	11	-6.04 (-12.08, 0.002; .05)	27
FVC, %	71.53	4.48 (0.14, 9.10; .06)	2.09 (-5.17, 9.34; .56)	10.36 (3.52, 17.20; .007)	23	11	2.11 (-4.27, 8.49; .50)	27
Creatinine, mg/dL	0.78	0.26 (0.04, 0.47; .02)	0.25 (0.07, 0.44; .009)	0.13 (0.04, 0.21; .008)	23	11	0.25 (0.10, 0.40; .003)	27
Ejection fraction, %	63.24	-0.21 (-3.60, 3.19; .90)	-2.84 (-5.80, 0.11; .06)	-3.85 (-7.22, -0.48; .03)	19	11	-2.37 (-4.80, 0.07; .06)	27

*Mean difference between baseline and last evaluation for 27 patients who survived more than 1 year in the indicated period. Confidence intervals (95%) are within parentheses. Each patient was compared with his own baseline result.
 †Mean difference between baseline and final evaluation after HDIT.

4.0; $P < .001$) from a mean baseline grade of 4.3. Using all available skin biopsies ($n = 40$) including from patients without samples from both before and after HDIT, a strong correlation was noted between the dermal fibrosis grades and the mRSS ($r = 0.62$, $P < .001$). The mean increase in FVC between baseline and final evaluation was 2.11% ($P = .50$), and DLCO_{adj} decreased by an average of 6.04% ($P = .05$). Considering all values across time, there was a statistically significant increase in FVC (increase of 1.66 per year [95% CI, 0.37 to 2.96], $P = .01$, GEE; Figure 2C) and DLCO_{adj} values were decreased, but this did not achieve statistical significance (decrease of 0.36 per year [95% CI, 1.42 to -0.69], $P = .50$; GEE; Figure 2D). The HRCT scans of the chest were centrally reviewed in 21 of the evaluable patients. No significant changes were observed after HDIT except for the 6 patients with reactivation of disease in the lungs. In 6 of 7 patients who survived at least 1 year and were centrally reviewed, “ground-glass” abnormalities at baseline decreased and evolved to interstitial fibrosis, and in the other patient the findings remained unchanged. There was a statistically significant but small increase in serum creatinine and decrease in ejection fraction (Table 4; Figure 2E,F). No patient experienced renal crisis or a significant loss of kidney function after the early treatment-related events. There was no statistically significant change in the ANA titer ($P = .26$). Of 11 patients who had a positive test for anti-Scl-70, 2 had become negative at last follow-up (6 and 8 years).

Among patients who survived more than 1 year, overall function as assessed by mHAQ was improved in 19 of 25 and disease responses were observed in skin of 23 of 25 and lung of 8 of 27 patients. All responders in lung had an improved FVC, and 2 patients also had an improved DLCO_{adj}. Disease activation was observed in 10 (37%) patients at a median of 1 (range, 1 to 6) years after HDIT. Disease activation or progression occurred in lung ($n = 6$), heart ($n = 1$), or in other systems that required DMARD treatment ($n = 3$). Four of 6 patients with lung disease activation/progression died at a median of 4 (range, 1 to 5) years after HDIT. A patient with disease activation in the lung also developed a new anti-Smith antibody at more than 3 years associated with new onset of thrombocytopenia. A second patient with disease activation who had the onset of a syndrome resembling rheumatoid arthritis and required DMARD therapy developed a newly positive rheumatoid factor at more than 1 year.

Infections

We previously reported a fatal Epstein-Barr virus (EBV)-associated posttransplantation lymphoproliferative disorder (PTLD) in 1 patient associated with changing from horse to rabbit ATG in the HDIT regimen.^{10,22} One case of CMV disease (gastroenteritis) occurred that resolved with antiviral treatment. Bacteremic episodes were observed in 11 patients and were usually associated with a central line. The microorganism identified in 6 of these bacteremic episodes was staphylococcus (coagulase negative). Three months after HDIT, infections were infrequent despite persistent lymphopenia. Reactivation of varicella zoster virus (VZV) (shingles) occurred in 6 patients at a median of 8 (range, 3 to 26) months after HDIT in patients not receiving preventive acyclovir (Table 5).

Regimen-related complications

Fatal pulmonary toxicities were observed in 2 of the first 8 patients on study and were previously reported.¹⁰ No further similar pulmonary events occurred after lung shielding was adopted for TBI. Renal crisis or dysfunction occurred in 6 patients, 3 of whom




Figure 2. Change in modified Rodnan skin score (mRSS), modified Health Assessment Questionnaire (mHAQ) score, and organ function after high-dose immunosuppressive therapy (HDIT) and autologous hematopoietic cell transplantation. A determination was made as to whether a parameter value was statistically significantly increasing or decreasing over time using a generalized estimating equation (GEE) model. The bold black solid line represents the mean value over time for the parameter of interest. The bold black dotted line represents an estimate of the modeled linear relationship between the parameter value and time and summarizes the results of the GEE models. The gray solid lines are parameter values for individual patients. The mean mRSS and mHAQ values statistically significantly decreased with time after HDIT (both $P < .001$; panels A and B, respectively). The mean values for diffusion capacity of the lung for carbon monoxide (DLCO) adjusted for hemoglobin levels did not statistically significantly change ($P = .50$, panel C), and forced vital capacity statistically significantly increased with time ($P = .01$, panel D). The mean values for serum creatinine and ejection fraction statistically significantly increased and decreased with time ($P = .01$ and $P = .04$; panels E and F, respectively).

had a history of renal crisis or renal dysfunction before study treatment. All adverse renal events first occurred less than 2 months after HDIT. Dialysis was required in 2 patients, but other complications developed after prolonged hospitalization and the patients died at day 123 and 191. A third patient required dialysis and died on day 14 after a sepsis syndrome (no microorganism isolated) and multiorgan failure. A fourth patient required dialysis for 20 months, but at 2 and 4 years without dialysis had serum creatinine levels of 212 and 274 $\mu\text{mol/L}$ (3.1 and 2.4 mg/dL), respectively. The final 2 patients had a doubling of serum creatinine but otherwise were clinically stable. Cardiovascular complications were supraventricular arrhythmias ($n = 2$), heart failure responsive to medication ($n = 2$), and hypertension. One patient with an abnormal pretreatment ejection fraction of 47% had a fatal arrhythmia at day 22. At autopsy, only SSc-related changes to the heart were observed.

Only 1 case of hypothyroidism developed at 12 months after HDIT among the 17 patients who were evaluable to 4 (range, 1 to 8) years after HDIT. In this single case, antithyroglobulin antibodies had been increased both before and after HDIT. In scheduled evaluations of the eye for 18 patients at last follow-up, only mild posterior subcapsular cataracts were observed in 2 patients. One patient developed neutropenia associated with a dysplastic marrow morphology and multiple cytogenetic abnormalities that were consistent with a diagnosis of myelodysplastic syndrome (MDS). A second patient died from complications related to MDS at 6 years after HDIT. Cytogenetic studies on both of the pretransplantation marrows had been normal. CD34⁺ cells or marrow that had been cryopreserved before transplantation in these 2 patients were thawed, and fluorescence in situ hybridization (FISH) studies were performed. In the pretransplantation CD34⁺ sample, 8.3% and

8.0% of the cells were positive for monosomy 5 and 7, respectively, both of which were present when the patient was diagnosed with MDS at 2 years after HDIT. No abnormalities were detected by FISH of the pretransplantation marrow on the other patient.

One patient with a 32-pack-year history of smoking cigarettes and who had lung shielding during TBI had a successful pneumonectomy at 5 years after HDIT for stage I non-small-cell lung carcinoma that had been detected at a routine CT scan of the chest.

Survival

There were 8 (23%) treatment-related and 4 (12%) disease-related deaths (Table 6). SSc-related organ dysfunction contributed to 6 of the 7 treatment-related deaths that occurred in the first year after HCT. There was 1 treatment-related event of renal failure that required dialysis for 20 months. Both the estimated overall and progression-free survival were 64% at 5 years (Figure 5).

Discussion

This report demonstrates a major decrease of the dermal fibrosis by histopathology associated with an improvement of the mRSS after standard treatment regimens or HDIT and autologous HCT for SSc. This suggests that the dermal fibrosis of SSc is in a dynamic state and disease activity is required to maintain it. Improvements of the skin and resolution of dermal fibrosis have also been observed in SSc patients after allogeneic HCT.^{23,24} No differences in mRSS were observed in a randomized clinical trial of methotrexate.²⁵ At 2 years in another clinical trial, patients with diffuse scleroderma




Figure 3. Resolution of dermal fibrosis after HDIT and autologous HCT. Full-thickness skin biopsies from patient no. 11, collected at baseline and then at 1 and 5 years after HDIT, were histologically evaluated (H&E). The skin biopsies performed after HDIT were performed at a site adjacent to the baseline skin biopsy. The biopsies in the left-hand column were taken at original magnification $\times 5$, and those in the right-hand column were taken at original magnification $\times 20$. All sections were stained with H&E. (A) Skin biopsy was obtained before HDIT and autologous HCT. Pandermal sclerosis from the dermal-epidermal border to the hypodermis (subcutaneous fat) was observed. The epidermis is mildly acanthotic (thickened) with loss of rete ridges. The reticular dermis is replaced by dense compact collagen without normal fascicular bundles or dermal appendages. This pretransplantation skin biopsy was determined as grade 5 dermal fibrosis. The thickness of the dermis was measured at more than 2 mm. (B) In the higher-power magnification, the straightened dermal-subcutaneous border demonstrates the abnormal, densely packed, homogenized collagen. (C) The skin biopsy at 1 year after HDIT was determined to be a grade 2 dermal fibrosis and has less fibrosis than at baseline. The low-power magnification view shows crowded collagen fascicles with focal areas of residual thickened bundles. (D) A higher-power view of the 1-year skin biopsy from panel C shows thin and collagen bundles admixed with residual thick straightened hyper eosinophilic collagen bundles without dense homogenization at baseline. The residual eccrine unit lacks any surrounding adipose tissue. (E) The skin biopsy at 5 years shows complete resolution of the dermal fibrosis (grade 0) with a reduction in the thickness of the dermis from baseline to 1 mm. The collagen bands in the dermis are thin with a relative increase in the intervening extracellular matrix (space between the collagen bands). The dermal-epidermal border remains straightened with loss of rete ridges. (F) A higher-power view of collagen in the lower reticular dermis demonstrates the change to thin wavy bundles separated by increased ground substance. See "Patients and methods; Assessment of skin biopsies" for more information on images.

had a mean decrease in mRSS of 4.8 and 6.9 in the low- and high-dose arms of D-penicillamine, respectively.⁶ A very modest but significant improvement in skin score was observed at 1 and 2 years in a recent randomized clinical trial of oral cyclophosphamide administered for 12 months.^{5,26} Patients with diffuse scleroderma in this study had a mean baseline mRSS of 21.0 ± 1.0 , and at 2 years the mRSS had decreased by 6.2 and 3.8 in the cyclophosphamide and placebo arms, respectively. This compares with a mean decrease of 17.6 at 1 to 2 years after HDIT and autologous HCT as reported in this study. In a recent report, a correlation was observed between the overall skin score and the grade of dermal fibrosis (graded 0 to 3).²⁷ Further in this report, a decrease in the grade of dermal fibrosis was observed in 4 of 5 patients after high-dose cyclophosphamide and autologous HCT (3 patients had a decrease of dermal fibrosis by 1 of 3 possible grades and 1 patient by 2 of 3 possible grades). The sclerosis grades




Figure 4. Change in dermal fibrosis grade and mRSS after HDIT and autologous HCT. The change in dermal fibrosis grade and mRSS was evaluated in patients from whom we had skin biopsies from both before and after HDIT and autologous HCT (n = 10). The mean decrease in skin score from baseline after HDIT was 19.7 ($P < .001$; left horizontal line) and was very comparable to the result for the overall group. The mean decrease in the dermal fibrosis grade from baseline was 3.1 ($P = .001$; right horizontal line) from a mean baseline grade of 4.3. Seven of the 10 patients had a dermal fibrosis grade of 0 to 1 at the time of last skin biopsy. The median follow-up was 4 (range, 1 to 6) years after HDIT and autologous HCT.

(mild, moderate, and severe) were based on a compilation of the degree of fibrosis in 4 different levels of dermis, with extra emphasis placed on fibrosis in the mid and deep reticular dermis. The dermal fibrosis grading system we developed in this study was based on the overall percentage of dermal sclerosis rather than its character or location. Because the follow-up was shorter, it is difficult to compare those results with our reported experience. However, we observed a mean decrease of 3 grades of a possible 5, and 7 of 10 patients had dermal fibrosis grades of only 0 or 1 at last follow-up after the more intensive HDIT including TBI. More importantly, both grading systems reflect the improvement in the skin score. The skin "remodeling" that has been reported after HDIT and either autologous or allogeneic HCT may be comparable to the "remodeling" of fibrotic bone marrow that was observed after successful allogeneic HCT for myeloproliferative disorders.²⁸ Progression in other organs was observed in some patients even though a skin response occurred.

In this clinical trial of HDIT, there were sustained responses at a median of 4 years consisting of a marked reduction in mRSS,

Table 5. Infections after HDIT for SSc

Infections	Frequency, no.		Site
	Less than 3 mo	More than 3 mo	
Virus			
EBV-associated PTLD	1	0	Systemic
Herpes simplex	3	0	Perianal, vaginal, oral
Cytomegalovirus			
Reactivation*	6	0	Blood
Disease	1	0	Gastrointestinal tract
Varicella zoster†	1	5	Skin
BK virus	1	0	Hemorrhagic cystitis
Bacteria			
Bacteremia	11	0	
Urinary tract infection	3	0	Bladder
Exit site infections	3	0	Central line, 2; J tube, 1
Osteomyelitis‡	1	0	Elbow
Cellulitis‡	1	0	Thumb
Aspiration pneumonia§	1	3	Lung
Fungus: <i>Aspergillus flavus</i>	1	0	Isolated skin (1 site)

Infectious events were ascertained until 2 years (or longer for VZV infections) after HDIT and autologous HCT.

*Cytomegalovirus reactivation was treated preemptively with antiviral therapy.

†Varicella zoster reactivation in patients not receiving antiviral prophylaxis.

‡Secondary to skin ulcer related to SSc.

§Late aspiration pneumonia events were attributed to abnormal esophageal function and gastric reflux associated with systemic sclerosis.

Table 6. Cause of death

Cause of death	No.	Time to event, mo after HDIT
Treatment related		
Respiratory failure: idiopathic pneumonitis + SSc	2	2, 2
EBV-PTLD	1	2
Renal crisis/failure	2	4, 6
Cardiac arrhythmia	1	0.5
Multiorgan failure and pulmonary hemorrhage	1	0.5
Myelodysplastic syndrome	1	76
Disease related		
Respiratory failure*	4	12, 44, 50, 59

*In 1 patient the terminal event was a gastrointestinal bleed.

improved overall function and, in general, clinically stable internal organ function. Although overall mortality at 5 years was 36% and treatment-related mortality was 23%, revisions to the treatment plan and better patient selection based on the experience obtained in the pilot study should significantly decrease the risk of treatment-related deaths even further. In the early phase of the experience with HDIT and autologous HCT reported by the European League Against Rheumatism/European Group for Blood and Marrow Transplantation (EULAR/EBMT), treatment-related mortality was 17%.²⁹ In an update of a randomized clinical trial conducted by the same group, there has been no treatment-related mortality or unexpected severe toxicities.³⁰ This was ascribed to better patient selection but also may relate to increased experience in managing patients with SSc in a transplantation program.

Although limited in number, other clinical trials of HDIT have been conducted. In a single center study of high-dose therapy with a single agent (cyclophosphamide or melphalan) and autologous HCT, major or partial responses were observed in 8 of 11 patients, but at a median of 18 months, 8 patients had not responded or had relapsed.³¹ Four (36%) patients had died by 18 months after HDIT. In a report from the European Group of Blood and Marrow Transplantation on 57 patients in their registry with a median follow-up of 20 months, the cumulative probability of disease progression at 5 years was 48% after treatment with mostly high-dose cyclophosphamide with or without T-cell-specific antibodies.²⁹ The cumulative probability of survival at 5 years was 72%. Skin responses were observed in both studies. The higher response rate that we observed in this study and was sustained for a median of 4 years may have resulted from the increased intensity of the pretransplantation immunosuppressive regimen with cyclophosphamide and ATG in combination with TBI. Increased intensity of the high-dose immunosuppressive therapy regimen has been associated with a lower relapse rate of the autoimmune disease.³²

Compared with baseline, there was a statistically but not clinically significant decrease of 7% in DLCO_{adj} at the final evaluation. There was a predictable, transient, early decrease in DLCO_{adj} with recovery by 6 to 12 months after HDIT, which is also observed in patients with normal lungs after HCT for hematologic malignancies.^{10,33} Six patients had disease activation/progression in the lungs, 4 of whom died. However, the average DLCO_{adj} remained stable over time when evaluated using the general estimating equation, and FVC remained stable or improved. There were small but statistically significant changes in serum creatinine levels and ejection fraction at final evaluation compared with baseline, but these changes were not clinically relevant for most patients. Visceral organ function in general remained stable after HDIT for most patients.

It has been previously reported that there was recovery of CD4⁺ T-cell counts at 2 years after HDIT. However, sustained

responses were observed in 63% of patients at a median of 4 years.^{10,12} Immune recovery after HDIT is associated with increasing thymic-derived naive CD4⁺ T cells with a decrease in memory T cells, an increase in regulatory T cells, and broader clonal diversity than was present before HDIT.^{12,34,35} These late immune changes support the conclusion that sustained responses may have resulted from the immunomodulatory effects of HDIT in addition to the early immunosuppression and depletion of autoreactive T cells. The development of new autoantibodies and clinical changes in the manifestations of the autoimmune disease after HCT might have been the natural history of the disease process. However, the immunomodulatory effects of HDIT and autologous HCT may have also resulted in the development of a second autoimmune disorder.³⁶

In the early phase of the pilot study, risks of HDIT specific to SSc were identified. Shielding of the lungs during TBI reduced the risks of pulmonary toxicity. EBV-associated PTLD developed only after equine ATG was replaced by rabbit ATG, so caution is necessary when adjustments to the intensity of the regimen are made and should be limited.²² Renal crisis/dysfunction was observed after HDIT, and it is not clear if some component of the treatment or supportive care contributed to this. Close monitoring of blood pressure and early intervention may mitigate the risk for development of renal crisis. Late adverse effects previously associated with higher doses of TBI such as hypothyroidism and cataracts were infrequent. MDS was diagnosed in 2 patients, 1 in whom pretransplantation chromosomal abnormalities were observed that were similar to the karyotypic changes of the MDS after HDIT and the other in whom a total dose of cyclophosphamide (more than 27 g) was administered before study treatment.^{37,38} Although high-dose chemoradiotherapy has been associated with an increased risk of secondary MDS or acute myelocytic leukemia (AML), the intensity of the pretransplantation chemotherapy appears to be an additional risk factor.^{39,40} A contributing factor to the development of the stage I non-small cell carcinoma of the lung in one of the patients was a history of smoking. In the modified HDIT regimen, lung radiation exposure is only 200 cGy. A higher risk of secondary solid tumors has also been observed after high-dose chemoradiotherapy for treatment of hematologic malignancies. However, TBI at doses below 1000 cGy did not increase the risk of secondary MDS/AML or solid tumors compared with chemotherapy-only regimens.^{39,41,42} All patients will require continued follow-up after HDIT to monitor stability




Figure 5. Survival and progression-free survival after high-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for systemic sclerosis. The estimated probability of survival and progression-free survival at 5 years was 64%. Tick marks represent censored observations.

of the disease and for late effects of treatment. Limiting cytotoxic therapy (eg, cyclophosphamide) before HDIT may help reduce the risk of late secondary malignancies.

In this pilot study with a median follow-up of 4 years, substantial improvement in skin involvement occurred, confirmed by clear histologic improvement or resolution of dermal fibrosis. This is the first description of this grading system for dermal fibrosis, and further studies on a second data set are required for validation if it is to be used as a clinical tool. There was also substantial improvement in overall function, and there was general stability of internal organ involvement overall. Patients included in this study were within 4 years from diagnosis with non-Raynaud symptoms of SSc, so it is unknown if similar results would be observed after HDIT in patients with longer duration of disease. Important clinical issues in the use of HDIT and autologous HCT for SSc were identified and led to successful protocol modifications. Future studies should consider renal shielding during TBI. The observations of sustained disease stabilization and improved function in this study were encouraging; however, we cannot be certain that this outcome is a significant improvement over the natural history of the disease. A National Institutes of Health (NIH)-sponsored randomized clinical trial (Scleroderma: Cyclophosphamide or Transplant [SCOT]) based on the pilot study described in this report is now being conducted in the United States that compares HDIT and autologous HCT to pulse cyclophosphamide.⁴³ In addition, a second randomized clinical trial (Autologous Stem Cell Transplantation International Scleroderma Trial [ASTIS]) is being conducted in Europe in which high-dose cyclophosphamide and autologous HCT are compared with pulse cyclophosphamide.

References

1. Steen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. *Arthritis Rheum*. 2000;43:2437-2444.
2. Bryan C, Knight C, Black CM, Silman AJ. Prediction of five-year survival following presentation with scleroderma: development of a simple model using three disease factors at first visit. *Arthritis Rheum*. 1999;42:2660-2665.
3. Mayes MD, Lacey JVJ, Beebe-Dimmer J, et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. *Arthritis Rheum*. 2003;48:2246-2255.
4. Furst DE. Rational therapy in the treatment of systemic sclerosis (review). *Curr Opin Rheumatol*. 2000;12:540-544.
5. Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. *N Engl J Med*. 2006;354:2655-2666.
6. Clements PJ, Furst DE, Wong WK, et al. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. *Arthritis Rheum*. 1999;42:1194-1203.
7. Pope JE, Bellamy N, Seibold JR, et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. *Arthritis Rheum*. 2001;44:1351-1358.
8. van Bekkum DW. Conditioning regimens for the treatment of experimental arthritis with autologous bone marrow transplantation. *Bone Marrow Transplant*. 2000;25:357-364.
9. McSweeney PA, Nash RA, Storb R, Furst DE, Gauthier J, Sullivan KM. Autologous stem cell transplantation for autoimmune diseases: issues in protocol development. *J Rheumatol*. 1997;24(suppl 48):79-84.
10. McSweeney PA, Nash RA, Sullivan KM, et al. High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes. *Blood*. 2002;100:1602-1610.
11. Clements PJ, Furst DE. Choosing appropriate patients with systemic sclerosis for treatment by autologous stem cell transplantation. *J Rheumatol*. 1997;24(suppl 48):85-88.
12. Storek J, Zhao Z, Lin E, et al. Recovery from and consequences of severe iatrogenic lymphopenia (induced to treat autoimmune diseases). *Clin Immunol*. 2004;113:285-298.
13. Sullivan KM, Dykewicz CA, Longworth DL, et al. Preventing opportunistic infections after hematopoietic stem cell transplantation: The Centers for Disease Control and Prevention, Infectious Diseases Society of America, and American Society for Blood and Marrow Transplantation Practice Guidelines and Beyond. *Hematology Am Soc Hematol Educ Program*. 2001:392-421.
14. Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G, Bowden RA. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. *Blood*. 1996;88:4063-4071.
15. Bernstein SH, Nademanee AP, Vose JM, et al. A multicenter study of platelet recovery and utilization in patients after myeloablative therapy and hematopoietic stem cell transplantation. *Blood*. 1998;91:3509-3517.
16. Bearman SI, Appelbaum FR, Buckner CD, et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. *J Clin Oncol*. 1988;6:1562-1568.
17. Clements PJ, Hurwitz EL, Wong WK, et al. Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial. *Arthritis Rheum*. 2000;43:2445-2454.
18. Clements PJ, Wong WK, Hurwitz EL, et al. The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trial. *Arthritis Rheum*. 2001;44:653-661.
19. Clements PJ, Wong WK, Hurwitz EL, et al. Correlates of the disability index of the health assessment questionnaire: a measure of functional impairment in systemic sclerosis. *Arthritis Rheum*. 1999;42:2372-2380.
20. Poole JL, Steen VD. The use of the Health Assessment Questionnaire (HAQ) to determine physical disability in systemic sclerosis. *Arthritis Care Res*. 1991;4:27-31.
21. Steen VD, Medsger TA Jr. The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. *Arthritis Rheum*. 1997;40:1984-1991.
22. Nash RA, Dansey R, Storek J, et al. Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases. *Biol Blood Marrow Transplant*. 2003;9:583-591.
23. Khorshid O, Hosing C, Bibawi S, et al. Nonmyeloablative stem cell transplant in a patient with advanced systemic sclerosis and systemic lupus erythematosus. *J Rheumatol*. 2004;31:2513-2516.
24. Nash RA, McSweeney PA, Nelson JL, et al. Allogeneic marrow transplantation in patients with

Acknowledgments

This work was supported by awards N01-AI-05419 from the National Institute of Allergy and Infectious Diseases, HL36444 from the National Heart, Lung, and Blood Institute, and CA15704 from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD

The authors acknowledge the study coordinators and data technicians who contributed to this study. We thank Helen Crawford, Bonnie Larson, Sue Carbonneau, and Jessica Fleenor for their excellent support in preparing this manuscript. We also thank Amgen for the gift of recombinant human G-CSF used in this study.

Authorship

Contribution: R.A.N., P.A.M., J.L.N., R.S., K.M.S., and D.E.F. were responsible for study concept and design; R.A.N., P.A.M., D.E.F., L.J.C., M.A., C.S.C., J.D.G., L.H., G.H., C.F.L., M.D.M., K.T.M., B.M., J.A.M., F.V., M.H.W., and J.R.S., acquisition of data; R.A.N., P.A.M., L.J.C., M.D.M., and D.E.F., analysis and interpretation; R.A.N., P.A.M., and D.E.F., writing of the manuscript; R.S. and K.M.S., obtaining funding; T.A.G., statistical analysis; R.A.N., P.A.M., D.E.F., L.J.C., C.S.C., M.A., and C.F.L., study supervision at collaborating sites; H.S., analysis of skin biopsies and development of the grading system; and J.D.G., central review of high-resolution computed tomography of the chest.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Richard A. Nash, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D1-100, PO Box 19024, Seattle, WA 98109-1024; e-mail: rnash@fhcrc.org.

- severe systemic sclerosis: resolution of dermal fibrosis. *Arthritis Rheum*. 2006;54:1982-1986.
25. Seyger MM, van den Hoogen FH, Vlijmen-Willems IM, Van de Kerkhof PC, de Jong EM. Localized and systemic scleroderma show different histological responses to methotrexate therapy. *J Pathol*. 2001;193:511-516.
 26. Clements PJ, Furst DE, Silver RM, et al. Outcomes at 24-months are better for patients who received one-year of cyclophosphamide (CYC) therapy for SSc alveolitis than in those who received one-year of placebo (PBO) in the Scleroderma Lung Study [abstract]. *Arthritis Rheum*. 2006;54:S522. Abstract 1252.
 27. Verrecchia F, Laboureaux J, Verola O, et al. Skin involvement in scleroderma - where histological and clinical scores meet. *Rheumatology*. 2007; 46:833-841.
 28. Anderson JE, Sale G, Appelbaum FR, Chauncey TR, Storb R. Allogeneic marrow transplantation for primary myelofibrosis and myelofibrosis secondary to polycythaemia vera or essential thrombocytosis. *Br J Haematol*. 1997;98:1010-1016.
 29. Farge D, Passweg J, van Laar JM, et al. Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry. *Ann Rheum Dis*. 2004;63:974-981.
 30. van Laar JM, Farge D, Tyndall A. Autologous Stem cell Transplantation International Scleroderma (ASTIS) trial: hope on the horizon for patients with severe systemic sclerosis. *Ann Rheum Dis*. 2005;64:1515.
 31. Farge D, Marolleau JP, Zohar S, et al. Autologous bone marrow transplantation in the treatment of refractory systemic sclerosis: early results from a French multicentre phase I-II study. *Br J Haematol*. 2002;119:726-739.
 32. Gratwohl A, Passweg J, Bocelli-Tyndall C, et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases. *Bone Marrow Transplant*. 2005;35:869-879.
 33. Horak DA. Pulmonary complications after hematopoietic cell transplantation. In: Blume KG, Forman SJ, Appelbaum FR, eds. *Thomas' Hematopoietic Cell Transplantation*. Oxford, United Kingdom: Blackwell Publishing; 2004:873-882.
 34. Muraro PA, Douek DC, Packer A, et al. Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. *J Exp Med*. 2005;201: 805-816.
 35. de Kleer I, Vastert B, Klein M, et al. Autologous stem cell transplantation for autoimmunity induces immunologic self-tolerance by reprogramming autoreactive T cells and restoring the CD4+CD25+ immune regulatory network. *Blood*. 2006;107:1696-1702.
 36. Loh Y, Oyama Y, Statkute L, et al. Development of a secondary autoimmune disorder after hematopoietic stem cell transplantation for autoimmune diseases: role of conditioning regimen used? *Blood*. 2007;109:2643-2648.
 37. Lillington DM, Micallef IN, Carpenter E, et al. Detection of chromosome abnormalities pre-high-dose treatment in patients developing therapy-related myelodysplasia and secondary acute myelogenous leukemia after treatment for non-Hodgkin's lymphoma. *J Clin Oncol*. 2001;19: 2472-2481.
 38. Abruzzese E, Radford JE, Miller JS, et al. Detection of abnormal pretransplant clones in progenitor cells of patients who developed myelodysplasia after autologous transplantation. *Blood*. 1999; 94:1814-1819.
 39. Metayer C, Curtis RE, Vose J, et al. Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study. *Blood*. 2003;101:2015-2023.
 40. Forrest DL, Hogge DE, Nevill TJ, et al. High-dose therapy and autologous hematopoietic stem-cell transplantation does not increase the risk of second neoplasms for patients with Hodgkin's lymphoma: a comparison of conventional therapy alone versus conventional therapy followed by autologous hematopoietic stem-cell transplantation. *J Clin Oncol*. 2005;23:7994-8002.
 41. Curtis RE, Rowings PA, Deeg HJ, et al. Solid cancers after bone marrow transplantation. *N Engl J Med*. 1997;336:897-904.
 42. Kolb HJ, Socie G, Duell T, et al. Malignant neoplasms in long-term survivors of bone marrow transplantation. Late Effects Working Party of the European Cooperative Group for Blood and Marrow Transplantation and the European Late Effect Project Group. *Ann Intern Med*. 1999;131:738-744.
 43. <http://www.sclerodermatrill.org>.